Aktieanalys

InDex Pharmaceuticals Q1’22: Brief Report Comment - Redeye

{newsItem.title}

Redeye Publicerad: 17 May 2022 10:47

Redeye leaves its comments on InDex Pharmaceuticals following its Q1 2022 report. Recent news includes management changes and minor news related to CONCLUDE, which seems to be progressing according to plan.

Länk till analysen i sin helhet: https://www.redeye.se/research/842178/index-pharmaceuticals-q122-brief-report-comment?utm_source=finwire&utm_medium=RSS

Nyheter om Flerie

Läses av andra just nu

Om aktien Flerie

Senaste nytt